Hey everyone; Looks like there is quite a bit of nervousness on the board at this time.
Here is a summation of how I see the company at this time.
First and foremost, remember why you bought the stock in the first place “the science” and the world renowned scientists that believe in the platform. Has everyone forgotten about the Mayo Clinic, Keith Knutson, Edith Perez, the 13.3 Mill grant from the DoD, Dart, Aztra Zeneca the FDA’s confidence in granting Fast track status as well as Orphan Drug designation?
Tapimmune’s science is in an area that has been unproven, but their initial Phase 1 study data in 2 indications were nothing short of spectacular, that data secured the confidence of both the FDA and the DoD no easy task.
To those who are trying to comment at this point that Tapimmune is a “scheme” or in some way not a legitimate representation of an up and coming Bio are simply not looking at the complete picture.
Once again I say to anyone to try to find a company that has as much potential moving forward as Tapimmune, in the Bio world, I completely understand how the lack of news regarding Data breeds uncertainty.
But like any great investment time is the equalizer, and at this point despite the lack of any material information the story is in the little details that have been constantly added to Tapimmune’s portfolio.
20 out of 21 patients had “robust” immune responses, if there is even a hint that the initial Phase 11 data responses are even close to those Phase 1...then look out. Does anyone on this board want to miss out on that possibility?
Their Polystart Platform construct, may make the presentation of Antigens even more potent [FOUR fold] in the Phase 11 trial Data, and may be used for infectious disease as well. Which has the potential down the road to be spun off as a completely separate company to shareholders, if there appears a potential suitor.
Their patent portfolio if the science proves out will be worth substantial monies.
The R/S to the up-list has both positive and negative contentions, but at this point is mute. People are throwing out possible R/S numbers at 1/20 1/16 which in my mind are to aggressive. I would think that 1/10 may even be too high.
Once you are up-listed on a major exchange you must have liquidity at 1/10 with let’s say min 100 mill O/S company would be left with 10 mill O/S at number leaves very little liquidity.
Not to mention how small the float would be with dart’s holdings. I believe that 1/10 will be excessive, but not out of the realm of possibility. Once again I am sure long standing investors who kept the company afloat may have some concern if the R/S is too aggressive.
I am a long time holder and long time future holder, if the R/S is very aggressive then I would look for a forward split down the road if the Initial Phase 11 results are stellar.
For the demand will far out way supply/available stock at 10 mill,for a major exchange.
I would think that the price [compared to other’s in the space] should be more in line with 20/30 or possibly more. Albeit that would be some years out [3] more.
There approach has yet to be proven, that is why there is so much skepticism at this point, but much more intelligent person’s than our selves have looked at and concluded that the potential is there...case in point DoD, Aztra etc.
Most of us here are committed to Tapimmune, and I still personally believe that the Phase 11 combined with their Polystart construct will also render strong results, is there the possibility the science will not produce the desired results...of course, that is the nature of a Bio.
But at this point all indications point to a favourable outcome, I for one will continue to add Pre and Post split.
There has been no evidence at any point in the companies history to comment that the company is a “scheme” as the company has constantly moved their science forward, and have accomplished many milestones. The company at this point looks very solid and a very attractive buyout candidate.
Other than the stock price [once again most probably noted to their unproven platform] there are very few, if any negatives to the science moving forward.
Do not let one or two disparage Tapimmune’s future, those people obviously have not done their DD, or think they have more intelligence than Keith Knutson, DoD, Dart, Aztra Zeneca and others.
Benefit’s include off the shelf application, very low cost, injections available at physicians office and potential to combat both Metastasis and a range of cancers, and infectious disease applications.
At this point with all the positives Tapimmune continues to offer great returns moving forward as well as bringing relief and possibly life saving potential to mill’s of cancer victims.
I do not have the time to post at this point, as my place is with my family/Grandson lost his leg to infection and my family is and always will be my first priority, but I continue to do DD on Tapimmune constantly.
Tapimmune will either be a monstrous success or simply a combination application that may prolong quality of life.
But it seems hard to assume that it will be a dismal failure with all prior Data and confidence instilled by scientist and corporate to date, I will accept consequences either way.
At this point I am still a long time holder and an acquirer of the stock, best of luck to everyone and God Bless.
BLU
